Cancer Treatment market research reports by DelveInsight

• CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) - Market Insight, Epidemiology And Market Forecast - 2032

  Feb 01, 2024  |  Published by: DelveInsight  |  USD 7,500

  CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) - Market Insight, Epidemiology And Market Forecast - 2032 Key Highlights In 2023, the market size of epidermolysis bullosa was highest in the US among the 7MM, accounting for approximately USD 1,300 million, which is further expected to increase by ... Read More

• Ocular Melanoma - Market Insight, Epidemiology And Market Forecast - 2034

  Jan 01, 2024  |  Published by: DelveInsight  |  USD 7,950

  Ocular Melanoma - Market Insight, Epidemiology And Market Forecast - 2034 Key Highlights Stargardt disease, also known as Stargardt’s macular dystrophy or juvenile macular degeneration, is a rare genetic eye disease that happens when fatty material builds up on the macula — the small part of the ret ... Read More

• Triple Negative Breast Cancer (TNBC) - Market Insight, Epidemiology And Market Forecast - 2032

  Nov 01, 2023  |  Published by: DelveInsight  |  USD 7,500

  Triple Negative Breast Cancer (TNBC) - Market Insight, Epidemiology And Market Forecast - 2032 Key Highlights Breast cancer is a genetically and clinically heterogeneous disease with multiple subtypes. The classification of these subtypes has evolved over the years. The most common and widely accept ... Read More

• Metastatic Non-Small Cell Lung Cancer - Market Insight, Epidemiology and Market Forecast -2032

  Nov 01, 2023  |  Published by: DelveInsight  |  USD 9,500

  Metastatic Non-Small Cell Lung Cancer - Market Insight, Epidemiology and Market Forecast -2032 Key Highlights NSCLC market size has seen a revolutionary change in the last decade owing to the increase in incident case of NSCLC, continuous uptake of approved therapies mainly immune checkpoint inhibit ... Read More

• HER2-Positive Breast Cancer - Market Insight, Epidemiology And Market Forecast - 2032

  Nov 01, 2023  |  Published by: DelveInsight  |  USD 9,500

  HER2-Positive Breast Cancer - Market Insight, Epidemiology And Market Forecast - 2032 Key Highlights Recent advancements in HER2 treatments have enhanced HER2-positive breast cancer management, yet relapse remains a primary challenge due to disease heterogeneity and drug resistance mechanisms. In 20 ... Read More

• Metastatic Prostate Cancer - Market Insight, Epidemiology And Market Forecast - 2032

  Nov 01, 2023  |  Published by: DelveInsight  |  USD 9,500

  Metastatic Prostate Cancer - Market Insight, Epidemiology And Market Forecast - 2032 DelveInsight's ""Metastatic Prostate Cancer - Market Insights, Epidemiology, and Market Forecast-2032"" report delivers an in-depth understanding of the metastatic prostate cancer, historical and forecasted epidemio ... Read More

• Metastatic HR+/HER2− Breast Cancer - Market Insights, Epidemiology, and Market Forecast-2032

  Nov 01, 2023  |  Published by: DelveInsight  |  USD 9,500

  Metastatic HR+/HER2− Breast Cancer - Market Insights, Epidemiology, and Market Forecast-2032 Key Highlights Breast cancer is a genetically and clinically heterogeneous disease with multiple subtypes. The HR+/HER2- subtype is the most common of all the breast cancer subtypes. The total market size in ... Read More

• Non-metastatic Prostate Cancer (nmPC) - Market Insight, Epidemiology and Market Forecast -2032

  Nov 01, 2023  |  Published by: DelveInsight  |  USD 7,500

  Non-metastatic Prostate Cancer (nmPC) - Market Insight, Epidemiology and Market Forecast -2032 Key Highlights Non-metastatic prostate cancer (nmPC) refers to prostate cancer that has not spread beyond the prostate gland and nearby lymph nodes. It is a localized form of prostate cancer. When prostate ... Read More

• Triple Negative Breast Cancer Epidemiology Forecast - 2032

  Sep 01, 2023  |  Published by: DelveInsight  |  USD 3,950

  Triple Negative Breast Cancer Epidemiology Forecast - 2032 Key Highlights Breast cancer is a genetically and clinically heterogeneous disease with multiple subtypes. The classification of these subtypes has evolved over the years. The most common and widely accepted classification of breast cancer i ... Read More

• Cutaneous T-Cell Lymphoma (CTCL)- Pipeline Insight, 2023

  Jul 01, 2023  |  Published by: DelveInsight  |  USD 2,000

  Cutaneous T-Cell Lymphoma (CTCL)- Pipeline Insight, 2023 DelveInsight’s, “Cutaneous T-Cell Lymphoma (CTCL)- Pipeline Insight, 2023” report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Cutaneous T-Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, ... Read More

• T cell Lymphoma -Pipeline Insight, 2023

  Jul 01, 2023  |  Published by: DelveInsight  |  USD 3,000

  T cell Lymphoma -Pipeline Insight, 2023 DelveInsight’s, “T-cell Lymphoma -Pipeline Insight, 2023” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in T-cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage p ... Read More

• Non Muscle Invasive Bladder Cancer- Pipeline Insight, 2023

  Jul 01, 2023  |  Published by: DelveInsight  |  USD 2,000

  Non Muscle Invasive Bladder Cancer- Pipeline Insight, 2023 DelveInsight’s, “Non Muscle Invasive Bladder Cancer- Pipeline Insight, 2023” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the pipeline d ... Read More

• Chemotherapy-induced peripheral neuropathy - Epidemiology Forecast - 2032

  Jun 01, 2023  |  Published by: DelveInsight  |  USD 3,950

  Chemotherapy-induced peripheral neuropathy - Epidemiology Forecast - 2032 Key Highlights Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent, dose-dependent complication of anticancer drugs, including platinum, taxanes, epothilones, vinca alkaloids, and newer agents, such as bortezomib. ... Read More

• Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS)-inhibitors – Market Insights, Epidemiology and Market Forecast – 2032

  Jun 01, 2023  |  Published by: DelveInsight  |  USD 7,500

  Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS)-inhibitors – Market Insights, Epidemiology and Market Forecast – 2032 Key Highlights: In Japan, the contribution of KRAS mutations is lower compared to Western countries like the United States and Europe In the United States, KRASG12C is present in ~ ... Read More

• Triple Negative Breast Cancer - Pipeline Insight, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 3,000

  Triple Negative Breast Cancer - Pipeline Insight, 2023 DelveInsight’s, “Triple Negative Breast Cancer - Pipeline Insight, 2023,” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Triple Negative Breast Cancer pipeline landscape. It covers the pipeline drug profiles ... Read More

• Anal Cancer - Pipeline Insight, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 1,250

  Anal Cancer - Pipeline Insight, 2023 DelveInsight’s, “Anal Cancer - Pipeline Insight, 2023” report provides comprehensive insights about 6+ companies and 8+ pipeline drugs in Anal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It a ... Read More

• Ovarian Cancer- Pipeline Insight, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 3,000

  Ovarian Cancer- Pipeline Insight, 2023 DelveInsight’s, “Ovarian Cancer- Pipeline Insight, 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage pro ... Read More

• Metastatic Uveal Melanoma - Pipeline Insight, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 1,500

  Metastatic Uveal Melanoma - Pipeline Insight, 2023 DelveInsight’s, “Metastatic Uveal Melanoma - Pipeline Insight, 2023,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Metastatic Uveal Melanoma pipeline landscape. It covers the pipeline drug profiles, including ... Read More

• Chemotherapy Drugs- Market Insights, Competitive Landscape, and Market Forecast - 2027

  Mar 01, 2023  |  Published by: DelveInsight  |  USD 2,750

  Chemotherapy Drugs- Market Insights, Competitive Landscape, and Market Forecast - 2027 Chemotherapy Drugs Market By Drug Class (Alkylating Agents, Mitotic Inhibitors, Antimetabolites, Topoisomerase Inhibitors, And Others), By Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer ... Read More

• Angioimmunoblastic T-cell lymphoma - Pipeline Insight, 2023

  Mar 01, 2023  |  Published by: DelveInsight  |  USD 1,500

  Angioimmunoblastic T-cell lymphoma - Pipeline Insight, 2023 DelveInsight’s, “Angioimmunoblastic T cell Lymphoma – Pipeline Insight, 2023,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Angioimmunoblastic T cell Lymphoma pipeline landscape. It covers the pipelin ... Read More

• HR Positive/ HER2 Negative Breast Cancer- Pipeline Insight, 2023

  Mar 01, 2023  |  Published by: DelveInsight  |  USD 2,500

  HR Positive/ HER2 Negative Breast Cancer- Pipeline Insight, 2023 DelveInsight’s, “HR Positive/ HER2 Negative Breast Cancer- Pipeline Insight, 2023” report provides comprehensive insights about 50+ companies and 53+ pipeline drugs in HR Positive/ HER2 Negative Breast Cancer pipeline landscape. It cov ... Read More

• HPV Testing and Pap Test- Market Insights, Competitive Landscape, and Market Forecast - 2027

  Feb 01, 2023  |  Published by: DelveInsight  |  USD 2,750

  HPV Testing and Pap Test- Market Insights, Competitive Landscape, and Market Forecast - 2027 HPV Testing And PAP Test Market By Test Type (Primary HPV Testing, Co-Testing, And Pap Test), By Application (Cervical Cancer, Vaginal Cancer, And Others), By Technology Type (Polymerase Chain Reaction, And ... Read More

• Chemotherapy induced diarrhea - Market Insight, Epidemiology And Market Forecast - 2032

  Jan 01, 2023  |  Published by: DelveInsight  |  USD 7,500

  Chemotherapy induced diarrhea - Market Insight, Epidemiology And Market Forecast - 2032 DelveInsight’s “Chemotherapy-induced Diarrhea (CID) – Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the CID, historical and forecasted epidemiology as wel ... Read More

• KEYTRUDA (pembrolizumab) Drug Insight and Market Forecast – 2032

  Dec 01, 2022  |  Published by: DelveInsight  |  USD 2,750

  KEYTRUDA (pembrolizumab) Drug Insight and Market Forecast – 2032 “KEYTRUDA (pembrolizumab) Drug Insight and Market Forecast – 2032” report provides comprehensive insights about KEYTRUDA (pembrolizumab) for Metastatic Colorectal Cancer (mCRC) in the 7MM. A detailed picture of the KEYTRUDA (pembrolizu ... Read More

• FASLODEX Drug Insight and Market Forecast – 2032

  Dec 01, 2022  |  Published by: DelveInsight  |  USD 2,750

  FASLODEX Drug Insight and Market Forecast – 2032 “FASLODEX Drug Insight and Market Forecast – 2032” report provides comprehensive insights about FASLODEX for ER +ve HER2-ve Breast Cancer in the United States. A detailed picture of the FASLODEX for ER+ve HER2-ve Breast Cancer in the United States for ... Read More

< prev 4 5 6 7 8 9 10 11 12 13 next >